Observational study / 2011
Direct-to-consumer genomewide risk profiling did not result in measurable short-term changes in dietary fat intake, exercise, or anxiety.
Researchers examined the psychological, behavioral, and clinical effects of risk scanning using the commercially available Navigenics Health Compass test. Among 2,037 subjects who completed follow-up at a mean of 5.6±2.4 months, primary analyses showed no significant differences between baseline and follow-up in anxiety symptoms (P=0.80), dietary fat intake (P=0.89), or exercise behavior (P=0.61). Test-related distress positively correlated with average estimated lifetime risk across conditions (β=0.117, P<0.001), though 90.3% of respondents had scores indicating no distress. There was also no significant increase in the rate of screening test use.
Shows an association, not proof of cause and effect.
- Study type
- Prospective cohort study
- Who was studied
- 2,037 subjects who completed follow-up out of 3,639 enrolled from health and technology companies
- What was measured
- Changes in anxiety symptoms, dietary fat intake, exercise behavior, test-related distress, and use of health-screening tests
THE PAPER
Effect of direct-to-consumer genomewide profiling to assess disease risk.
Bloss CS, Schork NJ, Topol EJ. N Engl J Med, 2011.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.